Clinical Operation Manager with background in Phase III and IV trials, experienced in all aspects of trial conduct from study start-up through close-out. A researcher with extensive background in preclinical oncology setting. Expertise in: Project Integration Management Project Time Management Project Scope Management Project Cost Management Project Risk Management Procurement Management Study Coordination Data Analysis Presentation & Final reports GCP GMP FDA HIPPAA US/Europe/Asia

1. Junbiao (Jim) Sang
3301 NW 67th
Street, Fort Lauderdale, FL 33309
sang66_98@yahoo.com (954) 732-8057 www.linkedin.com/in/Junbiaosang
Clinical Operation Manager with background in Phase III and IV trials, experienced in all aspects of trial
conduct from study start-up through close-out. A researcher with extensive background in preclinical
oncology setting. Expertise in:
Project Integration Management Project Time Management Project Scope Management
Project Cost Management Project Risk Management Procurement Management
Study Coordination Data Analysis Presentation & Final reports
GCP GMP FDA
HIPPAA US/Europe/Asia
PROFESSIONAL EXPERIENCE
Biotest Pharmaceuticals, Corp., Boca Raton, FL 2016 -2017
Associate Clinical Project Manager, Clinical Research 2016 -2017
Conducted two Phase IV clinical trials in primary Immune deficiency disease (PIDD)
 Selected CRO to conduct both trials.
 Played a major role in clinical study protocols amendments for FDA submission.
 Selected central and specialty labs for lab and PK testing.
 Selected IMP distributor and managed logistics for shipping and delivery of IMP to the sites.
 Selected trials sites and negotiated contract budgets.
 Point person for IRB submission.
 Organized Investigator meeting.
 Reviewed site monitoring reports.
 Managed projects per the scope of the work and within the contracted budget.
 Ensured trials conducted according to SOPs.
 Tracked plans to achieve contracted milestones (project plan, clinical management plan, monitoring
plan, training plan, communication plan).
 Monitored project progress and budget against contracts.
 Helped Phase III clinical trial close-out activities.
 Point person for global SOPs training within company.
 Reviewed and QC’d annual drug safety reports.
 Helped Drug Safety department when needed.
Synta Pharmaceuticals, Inc., Lexington, MA 2005 -2014
Manager/Scientist, in vivo Pharmacology 2005 -2014
Managed the in vivo pharmacology group to deliver results for company’s cancer, inflammation and
diabetes programs.
 Conducted and orchestrated all in vivo efficacy studies for single agent and combinations for cancer
projects.

2.  Coordinated all in-house studies including study design, scheduling, monitoring, interpreting and
prepared final reports.
 Managed projects involving academic collaborators and CROs as well across different departments to
evaluate compounds of interest.
 Managed in vivo Pharmacology group.
 Presented data at department, project and company meetings; wrote final monthly report.
 Involved in filing regulatory documents such as IND for cancer research projects.
Infinity Pharmaceuticals, Inc., Cambridge, MA 2003-2005
Senior Research Associate, in vivo Pharmacology 2003-2005
 Planned, designed and performed animal efficacy experiments and data analysis.
 Conducted PK and toxicity studies for company’s internal and external compounds of interest.
 Prepared study reports.
Millennium Pharmaceuticals, Inc., Cambridge, MA 1998-2003
Senior Research Associate, Process Technology 2001-2003
 Managed variety of research and development projects.
Senior Research Associate, Transcriptional Profiling 1999-2001
Lead multi-department team for developing transcriptional profiling methodologies and established a core
service group.
 Optimized technique and adapted for use in the different groups.
 Effected improvements in procedures for new technologies.
 Coordinated experiments to determine the best technology platform.
 Developed and implemented several QC methods to enhance the quality and consistency of results.
 Supervised technicians in the Hybridization Group of the Transcriptional Profiling Core.
Research Associate, Profiling biology 1998-1999
Hired to study various disease models including prostate cancer, congestive heart failure and inflammation
disease using different technologies.
Additional Experience:
Research Fellow Brown University/Rhode Island Hospital, Providence, RI
Physician People’s Hospital of Jiangsu, Nanjing, P.R. China
EDUCATION
M.S. in Biological Sciences University of Rhode Island, Kingston, Rhode Island
M.D. in Medicine Nanjing University School of Medicine, Nanjing, P.R. China
PROFESSIONAL DEVELOPMENT
CRA&CRC Certification Barnett International 2016
Clinical Project Management Fundamentals Certification Barnett International 2017
2

3. ASSOCIATIONS
Member of ACRP
PUBLICATIONS
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small
cell lung cancer.
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw
AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K,
Wada Y.
Invest New Drugs. 2012 Dec;30(6):2201-9. doi: 10.1007/s10637-011-9790-6. Epub 2012 Jan 10.
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak
V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.
Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in
mutant and wild-type non-small cell lung cancer.
Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug
metabolism.
Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta
N, Knowles MA, Bates RC, Proia DA.
Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA.
Invest New Drugs. 2014 Aug;32(4):577-86. doi: 10.1007/s10637-014-0095-4. Epub 2014 Apr 1.
mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA.
Mol Cancer Res. 2014 May;12(5):703-13. doi: 10.1158/1541-7786.MCR-13-0605. Epub 2014 Feb 19.
3

4. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with
ganetespib.
Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative
breast cancer.
Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J,
Smith DL, Sang J, Bates RC, El-Hariry I.
Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer
subtypes.
Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C, Proia DA.
Invest New Drugs. 2014 Feb;32(1):14-24. doi: 10.1007/s10637-013-9971-6. Epub 2013 May 18.
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen
receptor status or variant receptor expression.
He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia
DA.
Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, Proia DA.
Mol Cancer Ther. 2012 Dec;11(12):2633-43. doi: 10.1158/1535-7163.MCT-12-0615. Epub 2012 Sep 25.
The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting
microvasculature at both the center and periphery of tumors.
Foley KP, Zhou D, Borella C, Wu Y, Zhang M, Jiang J, Li H, Sang J, Korbut T, Ye J, Zhang X, Barsoum J,
Sonderfan AJ.
J Pharmacol Exp Ther. 2012 Nov;343(2):529-38. doi: 10.1124/jpet.112.196873. Epub 2012 Jul 26.
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and
in vivo models of non-small cell lung cancer.
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey
CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.
Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17.
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a
superior safety profile for cancer therapy.
4

5. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J,
Ogawa LS, Wada Y, Barsoum J, Koya K.
Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated
JAK/STAT signaling.
Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J,
Blackman RK.
PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K,
Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S.
Blood. 2010 Nov 25;116(22):4591-9. doi: 10.1182/blood-2009-10-247239. Epub 2010 Jul 22.
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an
anti-cancer agent directed against Hsp90.
Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J,
Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ,
Adams J, Tong JK.
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. Epub 2006 Nov 7.
5

6. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J,
Ogawa LS, Wada Y, Barsoum J, Koya K.
Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated
JAK/STAT signaling.
Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J,
Blackman RK.
PLoS One. 2011 Apr 14;6(4):e18552. doi: 10.1371/journal.pone.0018552.
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K,
Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S.
Blood. 2010 Nov 25;116(22):4591-9. doi: 10.1182/blood-2009-10-247239. Epub 2010 Jul 22.
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an
anti-cancer agent directed against Hsp90.
Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J,
Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ,
Adams J, Tong JK.
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. Epub 2006 Nov 7.
5